Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
Pediatric Cancer (Oncology)
Ewing Sarcoma (Non-Metastatic)
This randomized phase III trial studies combination chemotherapy to see how well it works compared to combination chemotherapy with topotecan hydrochloride in treating patients with non-metastatic extracranial Ewing sarcoma. Drugs used in chemotherapy, such as vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, ifosfamide, etoposide, and topotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known whether combination chemotherapy is more effective with topotecan hydrochloride in treating Ewing sarcoma.
Age less than or equal to 50 years
Newly diagnosed, biopsy confirmed, extracranial, non-metastatic Ewing sarcoma or PNET (Primitive neuroectodermal tumor) of bone or soft tissue
No prior chemotherapy or radiation therapy is allowed
Adquate kidney, liver, and heart function
Study status is:
Active, not recruiting:
The study is ongoing, and participants are receiving an intervention or being examined, but potential participants are not currently being recruited or enrolled.
Principal Investigator Name
Janice Olson, MD
Children's Cancer and Blood Disorders Program
Wednesday, January 27, 2021 11:41:12 AM